A practical reference on Nicotinamide riboside: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-22. Anything still debated is marked as such rather than presented as settled.
Small amounts of NMN occur in some foods, including certain vegetables, fruits, and animal products, though the quantities are generally low and variable. Human cells also synthesize NMN internally from nicotinamide and other precursors. Research interest increased after studies examined whether raising NAD+ levels affects metabolism and aging-related pathways in animals. Evidence in humans remains limited and mixed for many outcomes, and questions about effective absorption, tissue delivery, and long-term effects are still open. Regulatory status differs by country, with some markets treating NMN as a supplement ingredient and others restricting its sale.
Nicotinamide mononucleotide, usually shortened to NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide base linked to a ribose sugar that carries a phosphate group. In cells, NMN serves as an intermediate in the salvage pathway that produces nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in many oxidation-reduction reactions, NMN sits near central metabolic processes. The compound is not a drug in most jurisdictions and is discussed mainly in biochemistry and nutrition research.
The term NMN commonly refers to the beta isomer, in which the nicotinamide group is attached to the ribose through a beta-glycosidic bond. Commercial material may be supplied as the free acid or as a salt, such as a sodium salt, which affects molecular weight and water solubility. Related compounds include nicotinamide riboside and NAD+ itself, but these are distinct molecules with different formulas and cellular handling. Laboratory research often uses the beta form because it matches the naturally occurring configuration found in biological systems.
The biologically relevant form of NMN is generally the beta anomer, which is recognized by NMN adenylyltransferases. NMN is polar and water soluble, and it does not readily diffuse across lipid membranes without assistance. Whether intact NMN enters cells through a specific transporter remains an open question; some studies propose solute carrier family members, while other work favors extracellular dephosphorylation to nicotinamide riboside followed by uptake. This transport and compartmentalization debate affects how researchers interpret oral administration studies. The distinction between intracellular synthesis and extracellular delivery is central to current discussion.
Terminology around NMN can be confusing because several related compounds share the vitamin B3 family. Nicotinamide riboside is a nucleoside, whereas NMN is a nucleotide with a phosphate group, and NAD+ is a dinucleotide coenzyme rather than a simple precursor. Niacin and nicotinamide are also NAD+ precursors but follow different metabolic entry points. In commercial and scientific writing, NMN usually refers to beta-nicotinamide mononucleotide unless another form is specified. Consistent nomenclature helps distinguish chemical identity from proposed biological effects.
| Property | Value | Notes |
|---|---|---|
| Chemical name | beta-Nicotinamide mononucleotide | Free acid and salt forms share the core structure. |
| Molecular formula | C11H15N2O8P | Calculated for the free acid; salt forms add counterions. |
| Molar mass | 334.22 g/mol | Approximate value for the free acid form. |
| Appearance | White to off-white powder | Color and texture can vary with purity and salt form. |
| Solubility | Water-soluble | Typically soluble in aqueous media; less soluble in nonpolar solvents. |
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
== Discovery == Prohibitins are evolutionarily conserved genes that are ubiquitously expressed. The human prohibitin gene, located on the BRCA1 chromosome region 17q21, was originally thought to be a negative regulator of cell proliferation and a tumor suppressor. This anti-proliferative activity was later attributed to the 3' untranslated region of the PHB gene, and not to the actual protein. Mutations in human PHB have been linked to sporadic breast cancer. However, over-expression of PHB has been associated with a reduction in androgen receptor activity and a reduction in PSA gene expression resulting in a decrease of androgen-dependent growth of prostate cancer cells. Prohibitin is expressed as two transcripts with varying lengths of 3' untranslated region. The longer transcript is present at higher levels in proliferating tissues and cells, suggesting that this longer 3' untranslated region may function as a trans-acting regulatory RNA.
The body or shaft of the penis is the free portion of the human penis that is located outside of the pelvic cavity. It is the suspended middle portion of the organ, continuous proximally with the internal root and distally with the glans. Unlike the root, the body contains no muscle, consisting mostly of the corpora cavernosa, the corpus spongiosum and the spongy urethra, together with supporting skin, connective tissue, blood and lymphatic vessels and fascia. The corpora cavernosa are intimately bound to one another with a dorsally fenestrated septum, which becomes a complete one before the penile crura. The body of the penis is homologous to the female clitoral body.
While glass micropipette electrodes measure the sum of the currents passing through many ion channels, studying the electrical properties of a single ion channel became possible in the 1970s with the development of the patch clamp by Erwin Neher and Bert Sakmann. For this discovery, they were awarded the Nobel Prize in Physiology or Medicine in 1991. Patch-clamping verified that ionic channels have discrete states of conductance, such as open, closed and inactivated. Optical imaging technologies have been developed in recent years to measure action potentials, either via simultaneous multisite recordings or with ultra-spatial resolution. Using voltage-sensitive dyes, action potentials have been optically recorded from a tiny patch of cardiomyocyte membrane.
== Public image == It is hard to gauge the opinion of the Chinese public on Xi, as no independent surveys exist in China and mentions of his name in social media are heavily censored. However, he is believed to be widely popular in the country. According to a 2014 poll co-sponsored by the Harvard Kennedy School's Ash Center for Democratic Governance and Innovation, Xi ranked 9 out of 10 in domestic approval ratings. A YouGov poll released in July 2019 found that about 22% of people in mainland China list Xi as the person they admire the most, a plurality, although this figure was less than 5% for residents of Hong Kong. In the spring of 2026, the Pew Research Center made a survey on confidence on Xi among 36 countries, which indicated that a median 34% have confidence in Xi to do the right thing regarding world affairs, meanwhile a median of 53% have no confidence; these numbers are higher than those of Russian President Vladimir Putin (31% confidence, 65% no confidence) and United States President Donald Trump (23% confidence, 76% no confidence). In 2017, The Economist named him the most powerful person in the world. In 2018, Forbes ranked him as the most powerful and influential person in the world, replacing Russian President Vladimir Putin, who had been ranked so for five consecutive years. In 2022, Time also named Xi as the world's most powerful person, writing Xi "is the first among 1.4 billion people.
Sources: en.wikipedia.org
== Pharmacokinetics == When administered orally once a day, mavatrep reached steady-state in healthy volunteers in approximately 14 days. It has a relatively long half-life between 68 and 101 hours in Japanese subjects and between 82 and 130 hours in Caucasian subjects. Mavatrep is largely eliminated non-renally. Mavatrep appears to be metabolized into two primary metabolites which are also eliminated nonrenally.
== External links == FDA Summary of Juvéderm’s effectiveness and safety FDA: Physician’s instructions (intended use, contraindications, warnings and dosage) for using Juvéderm Raspaldo, Hervé; Gassia, Véronique; Niforos, François-Rene; Michaud, Thierry (2012). "Global, 3-dimensional approach to natural rejuvenation: Part 1 - recommendations for volume restoration and the periocular area". Journal of Cosmetic Dermatology. 11 (4): 279–289. doi:10.1111/jocd.12003. PMID 23174051.
== Related compounds == The chemical diversity within lichens includes a variety of compounds related to confluentic acid, reflecting the complex biosynthetic capabilities of these symbiotic organisms and their significance in lichen taxonomy and ecology. In 1987, Chicita Culberson and colleagues reported the use of high-performance liquid chromatography to isolate and identify additional higher-carbon analogue substances in the "confluentic series", including hyperconfluentic acid, superconfluentic acid, and subconfluentic acid. These substances were isolated from the lichen Pseudobaeomyces pachycarpa. The structure of subconfluentic acid (4-[2'-hydroxy-4'-methoxy-6'-(2"-oxopentyl)benzoyloxy]-2-methoxy-6-pentylbenzoic acid) was later established by synthesis. The compound 4-O-demethylsuperconfluentic acid, structurally similar to confluentic acid, was isolated from Stirtonia ramosa. Another analogue, 2-O-methylconfluentic acid, was identified from Lecidea fuscoatra. Gowan (1989) suggested a close chemical and biosynthetic relationship between methyl 2'-O-methylmicrophyllinate and confluentic acid, noting that the biosynthetic pathways leading to these compounds primarily differ in the length of the acetyl-polymalonyl segment. This means that the two compounds are synthesised through similar processes, differing mainly in the size of a specific chain within the molecule. Additionally, there is only a minor variation in their methylation patterns.
In 2000, John Pendry was the first to identify a practical way to make a left-handed metamaterial, a material in which the right-hand rule is not followed. Such a material allows an electromagnetic wave to convey energy (have a group velocity) against its phase velocity. Pendry hypothesized that metallic wires aligned along the direction of a wave could provide negative permittivity (dielectric function ε < 0). Natural materials (such as ferroelectrics) display negative permittivity; the challenge was achieving negative permeability (μ < 0). In 1999, Pendry demonstrated that a split ring (C shape) with its axis placed along the direction of wave propagation could do so. In the same paper, he showed that a periodic array of wires and rings could give rise to a negative refractive index. Pendry also proposed a related negative-permeability design, the Swiss roll. In 2000, David R. Smith et al. reported the experimental demonstration of functioning electromagnetic metamaterials by horizontally stacking, periodically, split-ring resonators and thin wire structures. A method was provided in 2002 to realize negative-index metamaterials using artificial lumped-element loaded transmission lines in microstrip technology. In 2003, complex (both real and imaginary parts of) negative refractive index and imaging by flat lens using left handed metamaterials were demonstrated. Negative index of refraction in the optical range was first demonstrated by Vladimir Shalaev et al. By 2007, experiments that involved negative refractive index had been conducted by many groups.
== Mechanism == Aspartate transaminase, as with all transaminases, operates via dual substrate recognition; that is, it is able to recognize and selectively bind two amino acids (Asp and Glu) with different side-chains. In either case, the transaminase reaction consists of two similar half-reactions that constitute what is referred to as a ping-pong mechanism. In the first half-reaction, amino acid 1 (e.g., L-Asp) reacts with the enzyme-PLP complex to generate ketoacid 1 (oxaloacetate) and the modified enzyme-PMP. In the second half-reaction, ketoacid 2 (α-ketoglutarate) reacts with enzyme-PMP to produce amino acid 2 (L-Glu), regenerating the original enzyme-PLP in the process. Formation of a racemic product (D-Glu) is very rare. The specific steps for the half-reaction of enzyme-PLP + aspartate
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a nucleotide composed of nicotinamide, ribose, and phosphate. In cells, it is an intermediate in NAD+ biosynthesis.
No, NMN and NAD+ are different molecules. NMN is a precursor that cells can convert into NAD+ through enzymatic steps. NAD+ is a larger dinucleotide that serves as a coenzyme in many reactions.
Nicotinamide riboside, or NR, is another NAD+ precursor but has a different structure. NR lacks the phosphate group present in NMN. Both are studied for their roles in NAD+ metabolism, yet they enter cellular pathways in different ways.
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide intermediate in NAD+ biosynthesis.